1. Medtech Insight
  2. >>Leadership
  3. >>Interviews

OneCell Diagnostics’ Mohan Uttarwar Discusses How AI Helps To Predict Cancer’s Next Move

Company Co-Founder Shares How Decoding Cancer At Single Cell Level Could Take Guesswork Out Of Recurrence With AI-Powered Diagnostics

 
• By Shubham Singh

Part 1 of 2: In an interview with Medtech Insight, Uttarwar breaks down how OneCell’s proprietary single cell biopsy platform is rewriting the rules of cancer diagnostics – not just identifying cancer at the cellular level but predicting its potential return with unprecedented accuracy. He also shares how the company’s approach leverages single cell biopsy technology and machine learning to spot signs of cancer’s return before it manifests clinically.

In an interview with Medtech Insight, Uttarwar breaks down how OneCell’s proprietary single-cell biopsy platform is rewriting the rules of cancer diagnostics

In a world where cancer remains one of the most complex and relentless diseases, OneCell Diagnostics, an artificial intelligence-powered cancer diagnostics startup from India, is taking a radically different approach to how it’s understood, detected, and treated. At the helm of this precision oncology startup is Mohan Uttarwar, the co-founder, a serial entrepreneur and biotech veteran who’s no stranger to building at the intersection of science and technology.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Interviews

‘AI Isn’t Flying Off The Shelves In The NHS,’ Says Healthtech Startup CEO

 
• By Natasha Barrow

Vendor exhaustion, insufficient clinical-grade evidence, and outdated risk management are some of the reasons the NHS is struggling to adopt AI. Haris Shuaib, CEO of Newton's Tree, shared his insights with the audience at the “Next Frontier of Medical AI” event held at DAC Beachcroft's London office on 23 April.

‘The FDA Will Be Looking For Avenues To Regulate Laboratory Developed Tests’

 
• By Natasha Barrow

The FDA's final LDT ruling was struck down in federal court last month. For now, diagnostic companies can commercialize under CLIA regulations or apply for FDA approval. McDermott and Tribun Health have shared insights on the risks, pros and cons of both regulatory routes.

First Liver Cancer Surveillance Test In Five Years Receives FDA Breakthrough Status

 
• By Natasha Barrow

Cambridge-based startup Mursla Bio's liquid biopsy test EvoLiver uses extracellular vesicles to detect hepatocellular carcinoma (HCC) in high-risk cirrhotic patients. Medtech Insight sat down with with Mursla Bio CEO Pierre Arsène.

Biolinq’s $100M In Series C Financing Supports Efforts To Bring Diabetic Glucose Monitoring With Needle-Free Patch To Market

 
• By Marion Webb

Biolinq plans to use the proceeds of its new venture funding to support US FDA de novo review, automation engineering and commercialization efforts with partners, CEO Rich Yang told Medtech Insight.

More from Medtech Insight

Q’Apel Medical Recalls, Discontinues Stroke Therapy System After FDA Warning Letter, Class I Designation

 
• By Brian Bossetta

Q’Apel Medical has pulled its aspiration system for stroke thrombectomy from the market after concerns raised by the US FDA in a February warning letter.

‘The FDA Will Be Looking For Avenues To Regulate Laboratory Developed Tests’

 
• By Natasha Barrow

The FDA's final LDT ruling was struck down in federal court last month. For now, diagnostic companies can commercialize under CLIA regulations or apply for FDA approval. McDermott and Tribun Health have shared insights on the risks, pros and cons of both regulatory routes.

Ireland’s Medtech Keeps Calm While Trump Covets Its Healthcare Industry

 
• By Amanda Maxwell

The Republic of Ireland’s record in life sciences is impressive. Decades of investment, education and training have been major winners for the country’s successful economy. But its success is drawing unwanted attention from the US. Trump wants “to have that.”